Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-07-15
2010-06-08
Bunner, Bridget E (Department: 1647)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S325000, C530S351000, C530S388100, C530S388240
Reexamination Certificate
active
07732146
ABSTRACT:
Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures:including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.
REFERENCES:
patent: 4284768 (1981-08-01), Santilli
patent: 4299814 (1981-11-01), Brandt et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4708937 (1987-11-01), Remold
patent: 5246869 (1993-09-01), Potter et al.
patent: 5328990 (1994-07-01), Wistow
patent: 5350687 (1994-09-01), Odink et al.
patent: 5352660 (1994-10-01), Pawson
patent: 5411882 (1995-05-01), Odink et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5597708 (1997-01-01), Holder et al.
patent: 5650295 (1997-07-01), Li et al.
patent: 5656596 (1997-08-01), Monard et al.
patent: 5656737 (1997-08-01), Wistow
patent: 5683887 (1997-11-01), Bucala et al.
patent: 5700447 (1997-12-01), Bucala et al.
patent: 5702920 (1997-12-01), Odink et al.
patent: 5733524 (1998-03-01), Bucala et al.
patent: 5733546 (1998-03-01), Bucala et al.
patent: 5733933 (1998-03-01), Bucala et al.
patent: 5780615 (1998-07-01), Bucala et al.
patent: 5801200 (1998-09-01), Bucala et al.
patent: 5821336 (1998-10-01), Odink et al.
patent: 5869534 (1999-02-01), Bucala et al.
patent: 5883224 (1999-03-01), Kirkpatrick et al.
patent: 5986060 (1999-11-01), Li et al.
patent: 6028081 (2000-02-01), Sada et al.
patent: 6030615 (2000-02-01), Bucala et al.
patent: 6080407 (2000-06-01), Bucala et al.
patent: 6214343 (2001-04-01), Kink et al.
patent: 6238874 (2001-05-01), Jarnagin et al.
patent: 6413939 (2002-07-01), Bucala et al.
patent: 6420188 (2002-07-01), Bucala et al.
patent: 7514225 (2009-04-01), Gaeta et al.
patent: 2003/0195194 (2003-10-01), Gaeta et al.
patent: 2004/0019921 (2004-01-01), Fingerle-Rowson et al.
patent: 2004/0204586 (2004-10-01), Sircar et al.
patent: 2005/0124604 (2005-06-01), Sircar et al.
patent: 592753 (1985-05-01), None
patent: 0020090 (1980-12-01), None
patent: 0162812 (1985-05-01), None
patent: 0 154 454 (1985-09-01), None
patent: 0 263 072 (1988-04-01), None
patent: 0 263 072 (1988-04-01), None
patent: 0 412 050 (1991-02-01), None
patent: 0 154 454 (1991-07-01), None
patent: 0 263 072 (1994-03-01), None
patent: 0 512 050 (1995-12-01), None
patent: 0900789 (1999-10-01), None
patent: 1424336 (2004-06-01), None
patent: 1500402 (2005-01-01), None
patent: WO 90/11301 (1990-10-01), None
patent: WO 94/20083 (1994-09-01), None
patent: WO 96/09389 (1996-03-01), None
patent: WO 96/15242 (1996-05-01), None
patent: WO 97/29635 (1997-08-01), None
patent: WO 97/39326 (1997-10-01), None
patent: WO 97/40159 (1997-10-01), None
patent: WO 9726307 (1997-11-01), None
patent: WO 98/17314 (1998-04-01), None
patent: WO 01/32606 (2001-05-01), None
patent: WO 02/07720 (2002-01-01), None
patent: WO 02/067862 (2002-09-01), None
patent: WO 02/079517 (2002-10-01), None
patent: WO 03/065979 (2003-08-01), None
patent: WO 03/104178 (2003-12-01), None
patent: WO 03/104203 (2003-12-01), None
patent: WO 2004/060881 (2004-07-01), None
patent: WO 2004/076679 (2004-09-01), None
Gao et al. An enzyme-liked immunosorbent assay to identify inhibitors of activation of platelet integrin alphaIIbbeta3. J Immunol Methods 181: 55-64, 1995.
Lederman et al. A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4. Mol Immunol. 28(11):1171-1181, 1991.
Li et al. beta-Endorphin omission analogs: dissociation of immunoreactivity from other biological activities.Proc Natl Acad Sci U S A. 77(6):3211-3214, 1980.
Skolnick et al. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotech 18(1): 34-39, 2000.
Bork, A. Powers and pitfalls in sequence analysis: the 70% hurdle. Genome Res 10: 398-400, 2000.
Doerks et al. Protein annotation: detective work for function prediction. Trends in Genetics 14(6): 248-250, 1998.
Smith et al. The challenges of genome sequence annotation or “The devil is in the details”. Nature Biotech 15: 1222-1223, 1997.
Brenner, S.E. Errors in genome function. Trends in Genetics 15(4): 132-133, 1999.
Bork et al. Go hunting in sequence databases but watch out for the traps. Trends in Genetics. 12(10): 425-427, 1996.
Ngo et al. Computational complexity, protein structure prediction, and the Levinthal paradox. The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495, 1994.
Substantive Examination report for corresponding Malaysia Patent Application No. PI 20021922, mailed on Dec. 31, 2005.
Morand et al. , Expert Opin. ther. Patents, vol. 13, pp. 1189-1212 (2003).
Riedemann et al., J. Clin. Invest., vol. 112, pp. 460-467 (2003).
U.S. Appl. No. 11/385,630, filed Mar. 20, 2006 to Sircar, et al.
Abe et al. 1993. “Induction of Vascular Endothelial Tubular Morphogenesis by Human Giloma Cells.”J. Clin. Invest. 92:54.
Abe et al. 2001. “Regulation of the CTL Response by Macrophage Migration Inhibitory Factor.”J. Immunol. 166:747-753.
Bacher et al. 1998. “MIF Expression in the Rat Brain: Implications for Neuronal Function.”Mol. Med. 4(4):217-230.
Baugh and Bucala. 2002. “Macrophage migration inhibitory factor.”Crit. Care Med. 30(1 Suppl.):S27-S35.
Bernhagen et al. 1995. “The emerging role of MIF in septic shock and infection.”Biotherapy8(2)123-7.
Bernhagen et al. 1993. “MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia.”Nature365:756-759.
Bernhagen et al. 1994. “Macrophage migration inhibitory factor is a neuroendocrine mediator of endotoxaemia.”Trends Microbiol. 2:198-201.
Bernhagen et al. 1998. “Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features.”J. Mol. Med. 76(3-4):151-161.
Bernhagen et al. 1998. “Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features.”J. Mol. Med. 76:151-161.
Bianchi et al. 1999. “Conformational Changes in Human Hepatisis C Virus NS3 Protease upon Binding of Product-Based Inhibitors.”Biochem. 38(42): 13844-13852.
Blocki et al. 1992. “Rat liver protein linking chemical and immunological detoxification systems.”Nature360:269-270.
Blocki et al. 1993. “MIF proteins are theta-class glutathione S-transferase homologs.”Protein Science2:2095-2102.
Bone et al. 1987. “A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock.” N. Eng. J. Med. 317: 653-658.
Bucala. 1994. “MIF, a Previously Unrecognized Pituitary Hormone and Macrophage Cytokine, Is a Pivotal Mediator in Endotoxic Shock.”Circulatory Shock44(1):35-30.
Bucala. 1996. “MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response.”FASEB J. 10:14):1607-1613.
Bucala. 1998. “Neuroimmunomodulation by Macrophage Migration Inhibitory Factor (MIF):”Ann. N. Y. Acad. Sci. 840:74-82.
Bucala. 2000. “A most interesting factor.”Nature408:146-147.
Calandra and Bucala. 1996. Macrophage Migration Inhibitory Factor: A Counter-Regulator of Glucocorticoid Action and Critical Mediator of Septic Shock.:J. Inflammation47:39-51.
Calandra and Bucala. 1997. “Macrophage Migration Inhibitory Factor (MIF): A Glucocorticoid Counter-Regulator within the Immune System.”Crit. Rev. Immunol. 17(1):77-88.
Calandra et al. 1994. “The Macrophage Is and Important and Previously Unrecognized Source of Macrophage Migration Inhibitory Factor.”J. Exp. Med. 179:1895-1902.
Calandra et al. 1995. “MIF as a glucocorticoid-induced modulator of cytokine produ
Anchin Jerry
Baird Andrew
Florkiewicz Robert
Gaeta Federico C. A.
K.C. Sunil Kumar
Avanir Pharmaceuticals
Bunner Bridget E
Knobbe Martens Olson & Bear LLP
LandOfFree
Method for screening an agent that modulates activity of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for screening an agent that modulates activity of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for screening an agent that modulates activity of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4199859